- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07748858
Improving Patient-Centered Care for Underserved Older African American Patients With Cardiovascular Comorbidities (PPC Heart)
Improving Patient-Centered Care for Underserved Older African American Patients With Cardiovascular Comorbidities: A Pilot Study of the Patient Priorities Care Approach at Cooper Green Mercy Health Services Authority (PPC-HEART)
Study Overview
Status
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Nardakafaria McNeill
- Phone Number: 205-934-0707
- Email: nmcneill@uab.edu
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35233
- Recruiting
- Cooper Green Mercy Hospital
-
Contact:
- Nardakafaria McNeill
- Phone Number: 205-934-0707
- Email: nmcneill@uab.edu
-
Principal Investigator:
- Deborah Ejem, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- greater than or equal to 50 years old
- at least one CVD (i.e., coronary artery disease, hypertension, heart failure, arrhythmias, cardiomyopathy, peripheral artery disease, stroke, and valvular heart disease)
- at least one coexisting chronic condition (i.e., inflammatory joint disease, COPD/asthma, diabetes, chronic kidney disease, and cancer one-year post-treatment)
- a caregiver of a participant, or a provider who serves this population.
Exclusion Criteria:
- Axis I psychiatric (schizophrenia, bipolar disorder), dementia, suicidal ideation,
- active substance use disorder nursing home or assisted living facility residence.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
|---|
|
Community Advisory Group (CAG) and Pilot Group
Nine of the 29 participants will participate in Aim 1 of the study, which involves convening a focus group to develop a culturally responsive version of the PPC Approach for underserved African Americans. This number was determined based on qualitative research best practices, which suggest that 6-10 participants per focus group allow for a diverse range of perspectives while maintaining an environment conducive to in-depth discussion. Additionally, this sample size aligns with previous studies that successfully used small, targeted focus groups to refine culturally tailored interventions. Twenty patients will participate in the pilot testing of the newly developed culturally responsive version of the PPC Approach. This number was determined to be satisfactory because it provides a sufficient sample to assess the feasibility and acceptability of the intervention while ensuring a manageable study scope. Prior feasibility studies have demonstrated that sample sizes between 15 and 30 par |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Older Patient Assessment of Chronic Illness Care (O-PACIC) Score
Time Frame: Baseline and eight weeks post- baseline.
|
Patient experience with integrated care delivery and self-management support measured using the 10-item Older Patient Assessment of Chronic Illness Care (O-PACIC) questionnaire.
Responses to the 10 items will be summed to calculate a total score ranging from 10 to 50.
Higher scores indicate more positive perceptions of chronic illness care.
Scores will be reported at baseline and 8 weeks post-baseline, along with the change from baseline.
|
Baseline and eight weeks post- baseline.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Treatment Burden Questionnaire (TBQ) Score
Time Frame: Baseline and eight weeks post- baseline
|
Perceived treatment burden measured using the 13-item Treatment Burden Questionnaire (TBQ).
Each item is rated from 0, indicating not a problem, to 10, indicating a big problem.
Item scores will be summed to calculate a total score ranging from 0 to 130. Higher scores indicate greater perceived treatment burden.
Scores will be reported at baseline and 8 weeks post-baseline, along with the change from baseline.
|
Baseline and eight weeks post- baseline
|
|
Perceived Shared Clinical Decision-Making (CollaboRATE Score)
Time Frame: Baseline and eight week post- baseline
|
Patient perception of involvement in shared decision-making measured using the 3-item CollaboRATE questionnaire.
Responses to the three items will be averaged to calculate an overall mean score ranging from 1 to 9. Higher scores indicate greater perceived involvement in shared decision-making.
Scores will be assessed at baseline and 8 weeks post-baseline, and change from baseline will be evaluated.
|
Baseline and eight week post- baseline
|
Collaborators and Investigators
Investigators
- Principal Investigator: Deborah Ejem, University of Alabama at Birmingham
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Urogenital Diseases
- Endocrine System Diseases
- Pathologic Processes
- Male Urogenital Diseases
- Kidney Diseases
- Urologic Diseases
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Chronic Disease
- Disease Attributes
- Metabolic Diseases
- Respiratory Tract Diseases
- Lung Diseases
- Glucose Metabolism Disorders
- Lung Diseases, Obstructive
- Renal Insufficiency
- Pathological Conditions, Signs and Symptoms
- Nutritional and Metabolic Diseases
- Multiple Chronic Conditions
- Pulmonary Disease, Chronic Obstructive
- Cardiovascular Diseases
- Diabetes Mellitus
- Renal Insufficiency, Chronic
Other Study ID Numbers
- IRB-300013717
- NIMHD (Other Identifier: National Institute on Minority Health and Health Disparities)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.